Ophthalmology Volume 130, Number 11, November 2023

中文摘要

這篇文章討論了近期美國發生的非處方潤眼液(over-the-counter artificial tears)引發感染事件對於病患和臨床醫師的影響。文章指出，在2023年2月2日的美國晚間新聞節目中報導了一種懷疑受污染的非處方潤眼液引發感染的事件。該事件起源於2022年5月洛杉磯出現兩宗眼部感染案例，而在2022年11月的流行病學調查中，發現了一種可疑的共同產品。隨後，美國食品和藥物管理局（FDA）和疾病控制與預防中心發出警告，並對生產商進行調查，指出其違反了良好製造規範。此外，作者還提出了病患應該注意的對策，以及對非處方潤眼液的管制和品質進行了深入討論。文章指出，美國需要提高對眼科製藥產品品質的認識，並呼籲臨床醫師密切關注藥品的化學、製造和控制。

English Abstract

The content discusses the implications of infections caused by contamination in over-the-counter artificial tears. A national alert was raised in the United States after reports of infections linked to a specific over-the-counter lubricant eye drop product. The FDA and CDC issued warnings about the product distributed by Delsam Pharma, leading to concerns about the quality and safety of all topical ophthalmic medications. The article highlights the need to increase awareness about the quality of ophthalmic pharmaceutical products, as well as the risks associated with compounded products from pharmacies. The author provides guidance for patients and recommends vigilance for signs of infection and discontinuation of recalled products. The content emphasizes the importance of ensuring the sterility and quality of ophthalmic medications to prevent potential public health crises.This content covers updates and safety communications from the United States Food and Drug Administration (FDA) regarding various medical devices and medications.